Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236175 | 0.72 | ALDH1A1 (0.43) | ALDH1A1POLBRXFP1HPGDNPC1 | |
| SCHEMBL12808514 | 0.71 | NR4A2 (0.47) | NR4A2CNR2POLBGAABRD4 | |
| SCHEMBL13013259 | 0.69 | NR4A2 (0.53) | CNR1NR4A2ALDH1A1CNR2POLB | |
| SCHEMBL2042835 | 0.68 | CNR1 (0.46) | PRPS1CNR1ALDH1A1CNR2GAA | |
| SCHEMBL6098691 | 0.67 | CNR2 (0.60) | CNR1NR4A2ALDH1A1CNR2POLB | |
| SCHEMBL20380141 | 0.67 | NR4A2 (0.55) | CNR1NR4A2CNR2POLBGAA | |
| SCHEMBL24143088 | 0.67 | CNR1 (0.39) | PRPS1CNR1ALDH1A1CNR2GAA | |
| SCHEMBL13166897 | 0.67 | NR4A2 (0.54) | CNR1NR4A2ALDH1A1CNR2POLB | |
| SCHEMBL20604971 | 0.66 | TDP1 (0.56) | PRPS1CNR1NR4A2ALDH1A1RXFP1 | |
| SCHEMBL6030646 | 0.65 | CNR1 (0.62) | CNR1NR4A2ALDH1A1CNR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010093789-A2 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | PRPS1 1895/4885CNR1 3001/4885NR4A2 3410/4885 |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | PRPS1 1895/4885CNR1 3001/4885NR4A2 3410/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | PRPS1 1445/4885CNR1 2209/4885NR4A2 4060/4885 |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | PDCD5, TP53, NUP205 | PRPS1 1518/4885CNR1 1930/4885NR4A2 4100/4885 |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | MCL1, BRCA1, IDO1 | PRPS1 3346/4885CNR1 203/4885NR4A2 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.